Abbott Healthcare, Medtronic India may move NPPA again to withdraw stents
Abbott Healthcare and Medtronic India say some high-end coronary stents have become commercially unviable after the NPPA's price caps
Mumbai: Abbott Healthcare Pvt. Ltd and Medtronic India Pvt. Ltd are likely to refile their applications with the National Pharmaceutical Pricing Authority (NPPA) to withdraw certain high-end coronary stents from the Indian market which they claim have become commercially unviable after government slashed prices by up to 85% in February.